

IBD INNOVATE™

NEW PRODUCT DEVELOPMENT FOR CROHN'S & COLITIS

December 4, 2019 • Metropolitan Pavilion, New York, NY



CROHN'S & COLITIS
FOUNDATION



Welcome to IBD INNOVATE 2019!

The Crohn's & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet needs of patients with IBD. In pursuit of this objective, the Foundation launched **IBD Ventures** to directly fund product discovery and development. Building on the launch of IBD Ventures, **IBD INNOVATE: New Product Development for Crohn's & Colitis™** will showcase the current innovative product development pipeline in IBD including novel therapies, diagnostics, devices, and digital health solutions. This second annual conference is an exceptional networking opportunity for all stakeholders dedicated to advancing innovative products to address the critical challenges faced by IBD patients.

Location

All conference programming will be held at the Metropolitan Pavilion, 125 West 18th Street, 5th floor, New York, NY 10011. Signs will direct you to locations for registration, talks, and 1:1 meetings upon your arrival. For 1:1 meetings, please use the Green Room.

Information and Registration

<http://www.crohnscolitisfoundation.org/ibdinnovate.html>

Social Media

Join today's conversation on social media using hashtag #IBDIInnovate

Contact

- **Program-related inquiries:**
entrepreneurship@crohnscolitisfoundation.org
- **Sponsorship-related inquiries:**
Nicholas Roman, nroman@crohnscolitisfoundation.org

AGENDA

Please note that this program is subject to change.

Welcome and Introduction

Welcome and Acknowledgements	Caren Heller, <i>Chief Scientific Officer, Crohn's & Colitis Foundation</i>	9:00 a.m.
Program Overview: Innovation to Address Unmet Needs in IBD	Andrés Hurtado-Lorenzo, <i>Senior Director of Translational Research, Crohn's & Colitis Foundation</i>	9:05 a.m.

Keynote

Designing Biology for Diagnostics and Therapeutics	Pamela Silver, <i>Professor, Harvard Medical School</i>	9:20 a.m.
---	---	------------------

Diagnostics

Diversity and Inclusion in Crohn's and Colitis Precision Medicine Research: What Will Success Look Like?	Elizabeth Cohn, <i>Rudin Professor of Nursing and Director of Nursing Research, Hunter-Bellevue School of Nursing, City University of New York and the Graduate Center, City University of New York</i>	10:05 a.m.
Towards Microbiome-based Prediction of IBD Biologics Treatment Outcomes	Angélique van 't Wout, <i>Co-founder and COO, AlphaBiomics</i>	10:25 a.m.

Break

10:40–10:55 a.m.

Devices

Semiflex Dome System for Vacuum Assisted Closure of Fistula Tracts in Crohn's Disease	Christianne Buskens, <i>Colorectal Surgeon, Amsterdam University Medical Centers</i> and Slawa Madelska, <i>Co-founder, Semiflex Dome System</i>	10:55 a.m.
Photo Biomodulation Treatment Technology for IBD	Sharon Ben Yehuda, <i>Co-founder and CEO, Photopill Medical</i>	11:10 a.m.
Programmable and Biomimetic Polymers for Tissue Reconstruction	Maria Pereira, <i>Chief Innovation Officer, Tissium</i>	11:25 a.m.

Therapeutics I

Long-acting GLP2R Agonist for Gut Regeneration and IBD	Weijun Shen, <i>Director, Metabolic Diseases, Scripps Research Institute</i>	11:40 a.m.
IMU-856: A Small Molecule Modulator Restoring the Gut Barrier Function	Hella Kohlhof, <i>Chief Scientific Officer, Immunic Therapeutics</i>	11:55 a.m.
TP-317: A Novel Immunoresolving Therapy for Inflammatory Bowel Diseases	Matthew Hanley, <i>VP of Research & Development, Thetis Pharmaceuticals</i>	12:10 p.m.

Lunch Served

12:25–1:20 p.m.

Patient Talk

Introduction	Michael Osso, <i>President and CEO, Crohn's & Colitis Foundation</i>	1:20 p.m.
Lessons from a Grateful Patient	Rolf Benirschke, <i>CEO, Legacy Health Strategies</i>	1:25 p.m.

Therapeutics II

BT-11: A Novel Gut-restricted First-in-class Therapeutic for Crohn's Disease and Ulcerative Colitis	Josep Bassaganya-Riera, <i>Chairman, President, and CEO, Landos Biopharma</i>	2:05 p.m.
Preclinical Development of BRD4 Inhibitors for the Treatment of Inflammatory Bowel Diseases	Jia Zhou, <i>Professor, University of Texas Medical Branch</i>	2:20 p.m.
Inhibiting Inflammation in IBD by Targeting Fbxo3	Michael Lark, <i>Project Leader, BioMotiv</i>	2:35 p.m.

Networking

2:50–3:25 p.m.

Precision Nutrition, Big Data, and Digital Health

Lilly is the exclusive sponsor of the Digital Health session at IBD Innovate.

Digital Therapeutics for IBD: Challenges, Opportunities and State of the Industry	Megan Oser, <i>Vice President, Clinical Innovation, Mahana Therapeutics</i>	3:25 p.m.
IBD Plexus®: Partnering to Accelerate IBD Research	Angela Dobes, <i>Senior Director, IBD Plexus, Crohn's & Colitis Foundation</i>	3:40 p.m.
Harnessing Microbiome Big Data for Prediction and Stratification	Aaron Del Duca, <i>Head, Microbiome Platform, DayTwo</i>	3:55 p.m.
Microbiome and Multiomic Modeling and Treatment of IBD	Christopher Mason, <i>Co-founder and Director, Onegevity</i>	4:10 p.m.

Microbiome Therapeutics

Developing Microbiome Therapeutics for Ulcerative Colitis	Jennifer Wortman, <i>Vice President, Clinical Discovery & Research Technology, Seres Therapeutics</i>	4:25 p.m.
Novel Therapeutic Platforms to Address Unmet Needs, Prevent, and Cure IBD	Scott Plevy, <i>Chief Scientific Officer, Synlogic</i>	4:40 p.m.

Poster Sessions

5:05–7:00 p.m.

POSTERS

Poster Location	Poster Title	Presenting Organization	Category
1	Oral Administration of Nanofitins for Treatment of Mucosal Inflammation—A Dual Targeting Approach	Affilogic	Small and large molecules
2	A Novel Gastrointestinal-targeted Immune Modulating Small Molecule Drug for Inflammatory Bowel Diseases	AIBIOS Co., Ltd	Small and large molecules
3	Peripheral Blood Methylation Profiles as Predictors of Response to Biologicals in IBD	Amsterdam University Medical Centers	Diagnostics
4	Small Molecule Kv1.3 Inhibition as An Orally Available Treatment of Inflammatory Bowel Diseases	D. E. Shaw Research	Small and large molecules
5	Bioelectronic Medicine: Outlook and Patient Perspective	Feinstein Institute	Devices
6	Synthetic Peptide (MTADV), Recognizing Serum Amyloid A (SAA), Ameliorates Chronic Inflammations, Including IBD: New Potential Drug (MTADV) and New Target (SAA)	Galmed Pharmaceuticals	Small and large molecules
7	Adrenomedullin (AM) and PEG-AM as A Potential Therapeutic Agent for IBD	Himuka	Small and large molecules
8	Reversing Disease Activity in Active Stage of DSS-induced Colitis in Mice by On-site Production and Delivery of CXCL12 by Transformed Lactic Acid Bacteria	Ilya Pharma	Small and large molecules
9	Antifibrotic Treatment Development for Strictures in Crohn's Disease	Johns Hopkins	Small and large molecules
10	An End-to-end Pipeline for Microbiome-based Treatments of IBD	Medbiome	Small and large molecules
11	Using High-precision Patient-first Discovery to Develop Live Bacterial Therapeutics for Ulcerative Colitis	Microbiotica	Microbiome and cell therapy
12	Digital Therapeutic to Improve the Quality of Life of Patients with Inflammatory Bowel Diseases	MyMee	Big data and digital health

POSTERS

Poster Location	Poster Title	Presenting Organization	Category
13	Targeted Colon Delivery of NIPEP-IM-0127 Peptide for Inflammatory Bowel Diseases (IBD) Treatment	Nano Intelligent Biomedical Engineering Corporation (NIBEC)	Small and large molecules
14	A Novel Device to Detect Complications Post Gastrointestinal Surgery	NERv Technologies	Devices
15	P28GST, an Innovative Helminth-based Therapeutic for Inflammatory Auto-immune Disorders	Par'Immune	Small and large molecules
16	Enterobacteriaceae-targeted Antiproliferative Agents to Treat Inflammatory Bowel Diseases	Symberix, Inc.	Microbiome and cell therapy
17	Application of Isolator Husbandry to Limit Gut Microbiome Variability	Taconic Biosciences	Research tools
18	A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Diseases	Thelium Therapeutics	Small and large molecules

More posters to be announced!

This conference is sponsored, in part, by:



About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immunoncology, epigenetics, immunology and neuroinflammation. For more information, please visit www.celgene.com. Follow Celgene on social media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.



About Lilly

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.



Inflammatory Bowel Diseases® is the official journal of the Crohn's & Colitis Foundation. Each issue contains cutting-edge, original basic science and clinical articles about diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in adult and pediatric IBD.

The *Journal* averages 25,000 full-text online views per month, and reaches a geographically diverse audience. Interested in submitting your research? Visit www.ibdjournal.org for author guidelines and more information.



Our mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

CROHN'S & COLITIS FOUNDATION
733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423